The DOI matches its Crossref record; 247 of the 247 references it cites were found in a registry or an index.
Nuclear receptors and nonalcoholic fatty liver disease
Open accessAbstract
Nuclear receptors are transcription factors which sense changing environmental or hormonal signals and effect transcriptional changes to regulate core life functions including growth, development, and reproduction. To support this function, following ligand-activation by xenobiotics, members of subfamily 1 nuclear receptors (NR1s) may heterodimerize with the retinoid X receptor (RXR) to regulate transcription of genes involved in energy and xenobiotic metabolism and inflammation. Several of these receptors including the peroxisome proliferator-activated receptors (PPARs), the pregnane and xenobiotic receptor (PXR), the constitutive androstane receptor (CAR), the liver X receptor (LXR) and the farnesoid X receptor (FXR) are key regulators of the gut:liver:adipose axis and serve to coordinate metabolic responses across organ systems between the fed and fasting states. Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease and may progress to cirrhosis and even hepatocellular carcinoma. NAFLD is associated with inappropriate nuclear receptor function and perturbations along the gut:liver:adipose axis including obesity, increased intestinal permeability with systemic inflammation, abnormal hepatic lipid metabolism, and insulin resistance. Environmental chemicals may compound the problem by directly interacting with nuclear receptors leading to metabolic confusion and the inability to differentiate fed from fasting conditions. This review focuses on the impact of nuclear receptors in the pathogenesis and treatment of NAFLD. Clinical trials including PIVENS and FLINT demonstrate that nuclear receptor targeted therapies may lead to the paradoxical dissociation of steatosis, inflammation, fibrosis, insulin resistance, dyslipidemia and obesity. Novel strategies currently under development (including tissue-specific ligands and dual receptor agonists) may be required to separate the beneficial effects of nuclear receptor activation from unwanted metabolic side effects. The impact of nuclear receptor crosstalk in NAFLD is likely to be profound, but requires further elucidation. This article is part of a Special Issue entitled: Xenobiotic nuclear receptors: New Tricks for An Old Dog, edited by Dr. Wen Xie.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–247 of 247
Yamamoto, Y., Moore, R., Flavell, R. A., Lu, B., & Negishi, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010121 · Cited by 59
Pregnane X Receptor Modulates the Inflammatory Response in Primary Cultures of Hepatocytes
Sun, M., Cui, W., Woody, S. K., & Staudinger, J. L. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062307 · Cited by 58
Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis
Fisher, C. D., Jackson, J. P., Lickteig, A. J., Augustine, L. M., & Cherrington, N. J. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0312-z · Cited by 57
Zhai, Y., Wada, T., Zhang, B., Khadem, S., Ren, S., Kuruba, R., Li, S., & Xie, W. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064618 · Cited by 57
CAR Suppresses Hepatic Gluconeogenesis by Facilitating the Ubiquitination and Degradation of PGC1α
Gao, J., Yan, J., Xu, M., Ren, S., & Xie, W. (2015) · Molecular Endocrinology · doi:10.1210/me.2015-1145 · Cited by 56
Kassam, A., Winrow, C. J., Fernandez-Rachubinski, F., Capone, J. P., & Rachubinski, R. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.6.4345 · Cited by 56
Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR
Wistuba, W., Gnewuch, C., Liebisch, G., Gerd, S., & Langmann, T. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i31.4230 · Cited by 55
Baskin-Bey, E. S., Huang, W., Ishimura, N., Isomoto, H., Bronk, S. F., Braley, K. E., Craig, R. W., Moore, D. D., & Gores, G. J. (2006) · Hepatology · doi:10.1002/hep.21236 · Cited by 55
Nan, Y., Kong, L.-B., Ren, W., Wang, R., Du, J., Li, W., Zhao, S., Zhang, Y., Wu, W., Di, H., et al. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-11 · Cited by 55
Xu, X. Y., Xu, X., Liu, P., Zhu, Z.-Y., Chen, J., Fu, H., Chen, L., Hu, L., & Shen, X. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.630475 · Cited by 55
Using Nuclear Receptor Activity to Stratify Hepatocarcinogens
Shah, I., Houck, K. A., Judson, R., Kavlock, R. J., Martin, M. T., Reif, D. M., Wambaugh, J. F., & Dix, D. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014584 · Cited by 54
Sulfotransferase genes: Regulation by nuclear receptors in response to xeno/endo-biotics
Kodama, S., & Negishi, M. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2013.835630 · Cited by 53
Laughter, A., Dunn, C. S., Swanson, C. L., et al. (2004) · Toxicology · doi:10.1016/j.tox.2004.06.014 · Cited by 51
Hsu, C.-W., Zhao, J., Huang, R., Hsieh, J., Hamm, J. T., Chang, X., Houck, K. A., & Xia, M. (2014) · Scientific Reports · doi:10.1038/srep06437 · Cited by 51
Ding, L., Pang, S., Sun, Y., Tian, Y., Li, Y., & Dang, N. (2014) · International Journal of Endocrinology · doi:10.1155/2014/751859 · Cited by 50
Lee, J.-Y., Hashizaki, H., Goto, T., Sakamoto, T., Takahashi, N., & Kawada, T. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.03.106 · Cited by 50
Pyrene is a Novel Constitutive Androstane Receptor (CAR) Activator and Causes Hepatotoxicity by CAR
Zhang, X., Shi, Z., Lyv, J.-X., He, X., Englert, N. A., & Zhang, S. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv142 · Cited by 50
Cariou, B., Hanf, Lambert-Porcheron, S., & Zair (2013) · Diabetes Care · Cited by 49
Nuclear Receptors in Nonalcoholic Fatty Liver Disease
López-Velázquez, J. A., Carrillo-Córdova, L. D., Chávez-Tapia, N. C., Uribe, M., & Méndez-Sánchez, N. (2012) · Journal of Lipids · doi:10.1155/2012/139875 · Cited by 48
PPARβ/δ Protects Against Experimental Colitis Through a Ligand-Independent Mechanism
Hollingshead, H. E., Morimura, K., Adachi, M., Kennett, M. J., Billin, A. N., Willson, T. M., Gonzalez, F. J., & Peters, J. M. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9644-9 · Cited by 48
Baskin-Bey, E. S. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i42.5635 · Cited by 47
Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease
Xu, J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i37.13493 · Cited by 44
Boesjes, M., Bloks, V. W., Hageman, J., Bos, T., van Dijk, T. H., Havinga, R., Wolters, H., Jonker, J. W., Kuipers, F., & Groen, A. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115028 · Cited by 44
Differential nuclear receptor signalling from DR4‐type response elements
Quack, M., Frank, C., & Carlberg, C. (2002) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10247 · Cited by 42
Effects of farnesoid X receptor on the expression of the fatty acid synthetase and hepatic lipase
Shen, L., Liu, H., Jiahe, P., Gan, L., Lu, L., Zhang, Q., Li, L., He, F., & Jiang, Y. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0140-0 · Cited by 41
FXR-dependent reduction of hepatic steatosis in a bile salt deficient mouse model
Kunne, C., Acco, A., Duijst, S., de Waart, D. R., Paulusma, C. C., Gaemers, I. C., & Elferink, R. P. J. O. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.02.004 · Cited by 41
Sberna, A.-L., Assem, M., Xiao, R., Ayers, S., Gautier, T., Guiu, B., Deckert, V., Chevriaux, A., Grober, J., Guern, N. L., et al. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.222497 · Cited by 41
The impact of pregnane X receptor activation on liver fibrosis
Wright, M. C. (2006) · Biochemical Society Transactions · doi:10.1042/bst0341119 · Cited by 38
Zhao, W., Liu, L., Wang, Y., Mao, T., & Li, J. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2846 · Cited by 38
Corton, J. C. (2008) · Critical Reviews in Toxicology · doi:10.1080/10408440802209796 · Cited by 37
Role of human pregnane X receptor in high fat diet-induced obesity in pre-menopausal female mice
Spruiell, K., Jones, D., Cullen, J. M., Awumey, E. M., Gonzalez, F. J., & Gyamfi, M. A. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.03.019 · Cited by 36
Archer, A., Venteclef, N., Mode, A., Pedrelli, M., Gabbi, C., Clément, K., Parini, P., Gustafsson, J.-Α., & Korach-André, M. (2012) · Molecular Endocrinology · doi:10.1210/me.2012-1151 · Cited by 33
Masuyama, H., & Hiramatsu, Y. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00167.2012 · Cited by 29
The nuclear receptor CAR modulates alcohol-induced liver injury
Chen, X., Meng, Z., Wang, X., Zeng, S., & Huang, W. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.68 · Cited by 28
Mozzicafreddo, M., Cuccioloni, M., Bonfili, L., Cecarini, V., Palermo, F. A., Cocci, P., Mosconi, G., Capone, A., Ricci, I., Eleuteri, A. M., et al. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.04.011 · Cited by 27
Na, T., Han, Y., Ka, N., Park, H., Kang, Y. P., Kwon, S. W., Lee, B., & Lee, M. (2014) · The Journal of Pathology · doi:10.1002/path.4494 · Cited by 25
Pathway-based toxicity: history, current approaches and liver fibrosis and steatosis as prototypes
Willett, C. (2014) · ALTEX · doi:10.14573/altex.1401283 · Cited by 23
Attia, A. M., El-Banna, S. G., Nomeir, F. R., & El-Basser, M. I. A. (2011) · PubMed · Cited by 22
Ohno, M., Kanayama, T., Moore, R., Ray, M. K., & Negishi, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115663 · Cited by 21
Greger, D. L., Gropp, F., Morel, C., Sauter, S. N., & Blum, J. W. (2005) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2005.12.002 · Cited by 20
Expression of Human CAR Splicing Variants in BAC-Transgenic Mice
Zhang, Y.-K. J., Lü, H., & Klaassen, C. D. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs321 · Cited by 15
Metabolic Functions of Peroxisome Proliferator-Activated Receptor β / δ in Skeletal Muscle
Gaudel, C., & Grimaldi, P. A. (2007) · PPAR Research · doi:10.1155/2007/86394 · Cited by 14
Host Genetic Variants in Obesity-Related Nonalcoholic Fatty Liver Disease
Mehta, R., Birerdinc, A., & Younossi, Z. M. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.09.017 · Cited by 14
Lau, A. J., Yang, G., & Chang, T. K. H. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.186130 · Cited by 13
Lau, A. J., & Chang, T. K. H. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12284 · Cited by 12
Je, Y.-T., Sim, W.-C., Kim, D.-G., Jung, B.-H., Shin, H., & Lee, B. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1268-9 · Cited by 12
Rahman, S. M., Choudhury, M., Janssen, R. C., Baquero, K. C., Miyazaki, M., & Friedman, J. E. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.11.027 · Cited by 10
Cited by
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Chen, H., Tan, H., Wan, J., Zeng, Y., Wang, J., Wang, H., & Lu, X. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108391 · Cited by 311
Roth, K., Yang, Z., Agarwal, M., Liu, W., Peng, Z., Long, Z., Birbeck, J., Westrick, J., Liu, W., & Petriello, M. C. (2021) · Environment International · doi:10.1016/j.envint.2021.106843 · Cited by 307
PPARs and nonalcoholic fatty liver disease
Liss, K. H. H., & Finck, B. N. (2017) · Biochimie · doi:10.1016/j.biochi.2016.11.009 · Cited by 275
Mechanisms Mediating the Regulation of Peroxisomal Fatty Acid Beta-Oxidation by PPARα
Tahri-Joutey, M., Andreoletti, P., Surapureddi, S., Nasser, B., Cherkaoui-Malki, M., & Latruffe, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168969 · Cited by 253
Metadata
- Authors
- Cave, M. C., Clair, H. B., Hardesty, J. E., Falkner, K. C., Feng, W., Clark, B. J., Sidey, J., Shi, H., Aqel, B. A., McClain, C. J., & Prough, R. A.
- Venue
- Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 1859
- Issue
- 9
- Pages
- 1083-1099
- ISSN
- 1874-9399 (ISSN-L)
- OpenAlex
- W2293546533
- Cited by
- 279
- References
- 247
- FWCI
- 22.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.